期刊
NEUROCHEMICAL RESEARCH
卷 38, 期 12, 页码 2474-2482出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11064-013-1161-6
关键词
A beta PP/PS1 mouse; Alzheimer's disease; Amyloid-beta peptides; Mesenchymal stem cells; Oxidative stress; beta-secretase 1
资金
- National Basic Research Program of China [2009CB526507]
- National Natural Science Foundation of China [81171214, 81371420]
- Shandong Province Natural Science Foundation [ZR2011HM064]
- science and technology project of Jinan city [200906011- 2]
Alzheimer's disease (AD) is characterized by Amyloid-beta (A beta) deposition in senile plaques in specific areas of the brain and by intraneuronal p-tau accumulation in neurofibrillary tangles. Cumulative evidence supports that oxidative stress is an important factor in the pathogenesis of AD and contributes to A beta generation. However, there is no effective treatment for AD. Human umbilical cord mesenchymal stem cells (HUMSCs) have potential therapeutic value for the treatment of neurological disease. However, the therapeutic impact of systemic administration of HUMSCs and their mechanism of action in AD have not yet been determined. Here, we found that intravenous infusion of HUMSCs significantly improved spatial learning and alleviated memory decline in an A beta PP/PS1 mouse model of AD. HUMSC treatment also increased glutathione (GSH) activity and ratio of GSH to oxidative glutathione as well as superoxide dismutase activity, while decreasing malondialdehyde activity and protein carbonyl level, which suggests that HUMSC infusion alleviated oxidative stress in A beta PP/PS1 mice. In addition, HUMSC infusion reduced beta-secretase 1 and CTF beta, thus reducing A beta deposition in mice. HUMSCs may have beneficial effects in the prevention and treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据